Skip to main content

Table 1 Demographic and clinical data of patients

From: Single-center experience of induction therapy in non-systemic vasculitic neuropathy

 

CS MONO

CYC MONO

CS PULSE MONO

Combination therapy

P-value

Count (n)

13

10

9

5

 

Sex (n) (male/female)

11/ 2

7/3

5/4

3/2

 

Age (years)

64 (52.5, 73)

70 (58.75, 77.25)

68 (60, 75.5)

59 (44.5, 74)

0.318

Pallesthesia (0–8)

2 (0, 3.5)

2 (0, 3.25)

2 (0, 3.5)

2 (0, 3.5)

0.998

CMAP tibial [mV]

0.4 (0.05, 1.05)

0.4 (0.075, 1)

1.3 (0.45, 3.8)

1.8 (0.3, 14.9)

0.148

SNAP sural [µV]

0.1 (0, 3.5)

0 (0, 2.25)

2 (0, 4.5)

0 (0, 0)

0.208

Disease duration before therapy (years)

1.5 (1, 4)

2 (1, 3.5)

2 (2, 3)

1 (0.79, 3)

0.299

  1. Values are expressed as the median and interquartile range (Q1, Q3). CS MONO: oral corticosteroid monotherapy; CYC MONO: cyclophosphamide monotherapy; CS PULSE MONO: pulsed intravenous corticosteroid monotherapy; combination therapy: therapy regimens combining immunosuppressants. Kruskal–Wallis tests were used to compare the data of each group
  2. Results with p < 0.05 were considered significant